COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments. The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa
The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness
Title : Interdependent antioxidant therapy in covid-19 and other critical diseases
Richard Z. Cheng, Cheng Integrative Health Center, United States
Title : Biotechnological exploration of phyto-drugs against MDR bacteria targeting DNA topoisomerase I and RNA polymerase
Asit Kumar Chakraborty, Vidyasagar University, India
Title : New excipient to formulate poorly soluble APIs
Rajendran Arunagiri, Eastman, United States
Title : Limiting factors in implementing pharmacovigilance principles in the elderly
Hana Hassan, University of Bristol, United Kingdom
Title : Intellection of molecular drug delivery models -an ayurvedic perspective
Ashtavaidyan Dr. E.T. Krishnan Mooss, Vaidyaratnam Group , India
Title : Evaluation of the wound healing activity of Hyoscyamus nigar seed powder on the wistar albino rats
Jeevanath Ruban, Trincomalee Campus, Sri Lanka
Title : Comparison of dexmedetomidine and propofol with ketofol in sedation of candidates for cataract surgery
Alireza Kamali, Arak University of Medical Sciences, Iran (Islamic Republic of)
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : Exosome-like nanoparticles from plants: Promising pharmaceutical preparations and delivery carriers
Chongzhi Liu, The First Affiliated Hospital of Chengdu Medical College, China